All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Regulatory agencies in Europe and the United States have approved two agents that target CD19 for the treatment of relapsed/refractory acute lymphoblastic leukemia in children and young adults: blinatumomab and anti-CD19 chimeric antigen receptor (CAR) T-cell tisagenlecleucel. It is known that both agents are associated with CD19 loss or downregulation. However, certain patients may receive both during the course of their treatments. Therefore, there is a high need to understand whether these treatments can be sequenced without inducing the development of resistance to CD19 targeting.
During 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Nirali Shah presented a talk on the impact on event-free survival (EFS) of using blinatumomab before CAR T-cell therapy.
Table 1. Baseline patient characteristics1
Blina, blinatumomab; CAR, chimeric antigen receptor; CNS3, central nervous system status 3; EM, extramedullary; MRD, measurable residual disease. |
|||
Pre-CAR disease status |
All (N = 420) |
Prior blina (n = 75) |
No blina (n = 345) |
---|---|---|---|
M1 or MRD-negative marrow, % |
51.6 |
53.3 |
51.3 |
M2/M3 marrow, % |
48.3 |
46.6 |
48.7 |
CNS3, % |
1.1 |
0.0 |
1.2 |
Active EM disease, % |
5.2 |
8.0 |
4.6 |
Circulating blasts, % |
15.9 |
18.7 |
15.3 |
KMT2Ar, % |
17.0 |
14.7 |
6.7 |
Table 2. Response to anti-CD19 CAR T-cell therapy1
Blina, blinatumomab; CAR, chimeric antigen receptor; CR, complete response. |
|||
Previous therapy |
CD19 CAR T-cell therapy response |
||
---|---|---|---|
CR |
Non-CR |
Total |
|
Blina, % |
14 |
3 |
17 |
No blina, % |
77 |
6 |
83 |
Total (N = 412), % |
91 |
9 |
100 |
Table 3. RFS and EFS at 6 and 12 months1
Blina, blinatumomab; EFS, event-free survival; NE, not estimable; RFS, relapse-free survival. |
||||||
Previous therapy |
6-month RFS, % |
12-month RFS, % |
Median RFS, months |
6-month EFS, % |
12-month EFS, % |
Median EFS, months |
---|---|---|---|---|---|---|
Blina |
63.4 |
57.5 |
20.3 |
49.7 |
46.7 |
5.8 |
No blina |
81.1 |
69.2 |
44.9 |
72.1 |
59.6 |
22.6 |
This study found that treatment with blinatumomab before CD19 CAR T-cell infusion was associated with significantly poorer outcomes in terms of RFS and EFS. Leukemic blast cells of patients who had been treated with blinatumomab showed more frequently a dim or no expression of CD19 antigens prior to CAR T-cell infusion and patients were at increased risk of not responding to CD19 CAR T-cell therapy.
The authors suggested that future studies should investigate whether there is an inherent risk for resistance to CD19 targeting in patients relapsing after blinatumomab and whether patients with prior blinatumomab might benefit from consolidation with hematopoietic stem cell transplantation.
Following up from the talk at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Regina Myers and colleagues published an article in the Journal of Clinical Oncology with an update on this study.1
For the whole cohort, the median follow-up was 30.1 months. Patients that were treated with blinatumomab (blina) but did not achieve a complete response (CR) showed a shorter relapse free survival (RFS), event free survival (EFS) and overall survival (OS) compared with blina-CR or blina-naïve (Table 1).
Table 1. CD19 response and survival outcomes at 24 months*
Outcome |
All |
Blina-No CR |
Blina-CR |
Blina-naïve |
---|---|---|---|---|
Median follow-up |
30.1 (21.0–48.1) |
32.4 (23.7−42.9) |
24.2 (18.3−36.0) |
30.8 (22.1−48.9) |
24-month RFS, % |
56.4 (50.8−61.6) |
22.7 (7.3−43.2) |
56.6 (37.9−71.6) |
58.6 (52.5−64.1) |
24-month EFS, % |
47.4 (42.3−52.3) |
13.7 (4.5−28.0) |
51.3 (34.2−66.1) |
50.2 (44.6−55.6) |
24-month OS, % |
65.1 (60.0−69.6) |
37.9 (21.0−54.8) |
76.5 (59.4−87.1) |
66.3 (60.8−71.3) |
Blina, blinatumomab; CAR, chimeric antigen receptor; CI, confidence interval; CR, complete response; EFS, event free survival; OS, overall survival; RFS, relapse free survival. |
A high disease burden was found to be associated with poor survival in this study. Blina use added to the negative impact of high disease burden for EFS and RFS but not OS. For blina non-responders, high disease burden prior to chimeric antigen receptor (CAR) T-cell infusion increased the chance of a poor outcome.
Following CD19 CAR T-cell therapy, 146 patients went on to receive a hematopoietic stem cell transplant (HSCT). Of these, 92 received HSCT within a year after CD19 CAR therapy, 13 had a previous transplant, and six had been given blina before. The median time from CAR T-cell infusion to HSCT was 93 days (range, 42–301 days).
Survival outcomes following HSCT were:
A relapse following HSCT occurred in 13.4% of patients, in two patients this was a relapse after a second HSCT.
Pre-CAR CD19 expression analysis was available for 414 patients. In blinatumomab exposed patients, dim CD19 or partial expression was seen more frequently compared with blina-naïve (13.3% vs 6.5%; p = 0.06). For blina patients with a strong CD19 positive expression before CAR treatment (n = 376), CR rates were 82.5%, a decrease compared with 92.9% in the blina-naïve patients (p = 0.01). Figure 1 shows a breakdown of relapse phenotype in both blina-naïve and blina-exposed patients, demonstrating that the phenotype at relapse was similar between the two groups.
Figure 1. CD19-positive expression in patients pre-CAR (n = 382)
Blina, blinatumomab.
*Adapted from Myers, et al.1
Compared with 95% of the blina-naïve patients, 62.5% of the blina-exposed patients reached CR in patients with CD19-dim or partial expression (p = 0.06). All five of the blina-exposed patients who achieved CR subsequently relapsed. Of the 28 patients with CD19-dim expression before CAR T-cell infusion, 60.7% experienced a relapse or nonresponse. Patients who were given blina and then became CD19-dim showed particularly poor outcomes (Figure 2).
Figure 2. CD19-dim expression in patients pre-CAR (n = 29)*
Blina, blinatumomab.
*Adapted from Myers, et al.1
While blina exposure does not preclude a response to CD19 CAR T-cell therapy, blina-exposed non-responders were found to have poorer outcomes than blina-naïve or previous blina-responders. Blina exposed non-responders demonstrated lower CR rates coupled with increased incidence of relapse compared with blina-naïve patients. Blina use may result in CD19 downregulation, in patients where CD19 expression was reduced following treatment CD19 negative disease relapse was common.
Subscribe to get the best content related to ALL delivered to your inbox